Background: Thoracic surgery patients are at high-risk for adverse pulmonary outcomes. Heated humidified highflow nasal cannula oxygen (HHFNC O 2 ) may decrease such events. We hypothesized that patients randomized to prophylactic HHFNC O 2 would develop fewer pulmonary complications compared to conventional O 2 therapy. Methods and patients: Fifty-one patients were randomized to HHFNC O 2 vs. conventional O 2 . The primary outcome was a composite of postoperative pulmonary complications. Secondary outcomes included oxygenation and length of stay. Continuous variables were compared with t-test or Mann-Whitney-U test, categorical variables with Fisher's Exact test. Results: There were no differences in postoperative pulmonary complications based on intention to treat [two in HHFNC O 2 (n = 25), two in control (n = 26), p = 0.680], and after exclusion of patients who discontinued HHFNC O 2 early [one in HHFNC O 2 (n = 18), two in control (n = 26), p = 0.638]. Discomfort from HHFNC O 2 occurred in 11/25 (44%); 7/25 (28%) discontinued treatment. Conclusions: Pulmonary complications were rare after thoracic surgery. Although HHFNC O 2 did not convey significant benefits, these results need to be interpreted with caution, as our study was likely underpowered to detect a reduction in pulmonary complications. High rates of patient-reported discomfort with HHFNC O 2 need to be considered in clinical practice and future trials.
Background
Postoperative pulmonary complications are prevalent following major thoracic surgery with a risk up to 25% following lung resection [1] . Risk factors in this patient population include severe baseline pulmonary disease, smoking, lung collapse during surgery, resection of viable lung, and poor pain control after a thoracotomy incision. Development of postoperative respiratory failure following major surgery is associated with a mortality of up to 27%, compared to 1% in patients without respiratory failure [2] . Atelectasis formation is a key factor for the development of such postoperative pulmonary complications. Unfortunately, the occurrence of atelectasis is extremely common postoperatively, with an incidence of up to 85% [3] and it significantly increases the risk for pneumonia and acute hypoxic respiratory failure [4] .
Non-invasive ventilation has emerged as a successful strategy for both the prevention and treatment of postoperative acute respiratory failure in high-risk surgical patients [5] [6] [7] [8] [9] . Non-invasive ventilation generates positive airway pressure, thereby improving atelectasis and systemic oxygenation [10] . For example, in patients with acute respiratory failure following lung resection, the use of non-invasive ventilation has been shown to decrease the incidence of re-intubation from 50% to 21% [11] . Non-invasive ventilation, however, has important limitations, such as the need for a face-mask that usually covers the nose and mouth possibly leading to claustrophobia, prevention of normal oral intake, possibly less effective clearance of secretions, and prevention of usual communication with family members and medical staff [12] . Furthermore, in thoracic surgery, the potential for positive pressure ventilation to increase stress on surgical suture lines as well as concerns for exacerbation of bronchopulmonary fistulas have tempered enthusiasm for the prophylactic use of non-invasive ventilation [13] .
Heated humidified high-flow nasal cannula oxygen (HHFNC O 2 ) is an alternative to standard oxygen therapy and non-invasive ventilation. This therapy involves high flows of oxygen (up to 60 + L per minute) delivered through a modified nasal cannula. This treatment may provide many of the same respiratory advantages of non-invasive ventilation, without the significant drawbacks including patient discomfort, cost, and medical expertise [14] . Indeed, HHFNC O 2 has been used successfully to reduce rates of re-intubation in a low-risk mixed medical/surgical ICU population [15] . Similarly, it has been shown that HHFNC O 2 appears to be non-inferior to non-invasive ventilation in preventing re-intubation in high-risk ICU patients [16] -a finding that was also confirmed specifically in cardiothoracic surgery patients [17] . Here, we sought to test the hypothesis that prophylactic use of HHFNC O 2 in patients admitted to the ICU after thoracic surgery would have fewer postoperative pulmonary complications compared to patients treated with conventional O 2 therapy.
Methods

Trial design
This prospective randomized trial was conducted from August 2013 to June 2015 at an academic medical center in the United States. The institutional review board approved the study protocol before patient enrollment. Participants gave their written informed consent to participate in the trial. No incentive was paid for agreeing to participate. This study was reported using the CONSORT statement for the reporting of randomized clinical trials [18] . The trial was retrospectively registered at ClinicalTrials.gov on January 10, 2017 (NCT03024112).
Participants
Eligible patients were ≥18 years of age undergoing thoracic surgery with scheduled admission to the intensive care unit postoperatively. Exclusion criteria were age b 18, pregnant or breastfeeding, a known diagnosis of obstructive sleep apnea, current or previous lung transplantation, previous pneumonectomy, home oxygen N 4 L/min, or inability to adhere to assigned treatment for the intended duration (48 h after surgery or until transfer to the floor, whichever occurred earlier). Baseline data and patient demographics were recorded and included age, gender, height, weight, American Society of Anesthesiologists physical status, smoking history, duration of surgery and onelung ventilation, intraoperative fluids, Simplified Acute Physiology Score, as well as surgical procedure.
Interventions
After completion of surgery and upon arrival to the post-anesthesia care unit, a sealed envelope was opened by a member of the study team to determine if subjects had been randomized to the HHFNC O 2 versus the standard O 2 treatment group (1:1 allocation).
The intervention group received HHFNC O 2 at a set flow of 40 L/min. FiO 2 was titrated by respiratory therapists to maintain SpO 2 ≥ 90%. The HHFNC O 2 apparatus (MaxVenturi®, Maxtec, Salt Lake City, UT, USA) included: 1.) Air-Oxygen blender -capable of delivering 21-100% FiO 2 at flow rates up to 60 L/min, 2.) Heated Humidifier -providing active heating and humidification to the delivered air-O 2 blend, 3.) Nasal cannula -larger diameter, slightly elongated nasal cannula with single limb connection to humidifier, 4.) O 2 analyzer-routinely calibrated during the study. The standard O 2 treatment group received usual nasal cannula or face mask oxygen titrated by nurses as necessary to maintain SpO 2 ≥ 90%. Patients were recovered from anesthesia in the post-anesthesia care unit and then transferred to the ICU. Allocated therapy continued for a total of 48 h or until transfer from the ICU to the floor. Given the apparent differences in the technical apparatus to administer HHFNC O 2 versus standard oxygen therapy, blinding procedures could not be performed.
If patient intolerance to HHFNC O 2 developed as assessed clinically by nursing, respiratory therapy, or physician care team, HHFNC O 2 therapy was discontinued, and reasoning for discontinuation was recorded. If a patient developed impending or acute respiratory failure while enrolled in the study, allocated study treatment was discontinued, and treatment decisions for escalation of therapy (non-invasive ventilation, re-intubation) were be made by the patient's care team.
Outcomes
Primary study outcome was the occurrence of the composite of postoperative pulmonary complications defined as: severe hypoxemia (SpO 2 b 90% with FiO 2 ≥ 50%), acute respiratory failure (dyspnea at rest, respiratory rate N 25 breaths/min, active use of accessory respiratory muscles, PaO 2 /FiO 2 ratio b 200), escalation of therapy to non-invasive ventilation, re-intubation, occurrence of hospital-acquired pneumonia, or re-admission to the ICU. Secondary outcomes included ICU length of stay, hospital length of stay, and postoperative oxygenation.
Statistical methods
Categorical variables including the primary outcome "postoperative pulmonary complications" were compared with Fisher's Exact test. Since we only assessed one primary outcome variable, no adjustment for multiple comparisons was made. After testing for normality of distribution within treatment groups using Shapiro-Wilk test, continuous variables were compared with independent t-test not assuming equal variances or Mann-Whitney-U test as appropriate. Statistical significance was assumed at a level of significance of p b 0.05 (one-sided for primary outcome, two-sided for other variables) using SPSS Version 24, Copyright IBM Corporation. Based on historical data from our institution from September 2011 until August 2012, the incidence of the primary outcome was expected to be 61%. Assuming a 58.4% relative reduction in the incidence of acute respiratory failure [11] , a total sample size of 52 patients (26 per group) would have given us 81% power to detect a difference in the incidence of postoperative pulmonary complications using Fisher's Exact test with a one-sided tail and significance at p = 0.05. Power analysis was performed using G*Power 3.1 [19] .
Results
A total of 51 patients were randomized in the trial. Seven patients allocated to the HHFNC O 2 arm of the trial did not tolerate the treatment, and HHFNC O 2 was therefore discontinued (Fig. 1 ). An additional four patients reported discomfort with the HHFNC O 2 device but continued treatment. Baseline characteristics of the study population are reported in Table 1 .
Based on intention to treat, postoperative pulmonary complications, the primary outcome, was detected in two patients (8%) within the HHFNC O 2 group and two patients (8%) in the conventional O 2 group (p = 0.680). Following exclusion of seven patients who discontinued HHFNC O 2 early due to discomfort, postoperative pulmonary complications occurred in one patient within the HHFNC O 2 group and two patients in the conventional O 2 group (Table 2) . No patient from the control cohort required escalation from conventional O 2 to HHFNC O 2 therapy. One patient was diagnosed intra-operatively with a condition that required a separate surgery at a later date. Following the second surgery, this patient was again admitted to the ICU postoperatively. This admission to the ICU was not counted as an ICU readmission for the purpose of this study. Analysis of secondary outcomes revealed no difference between groups except for the number of hourly measurements of SpO 2 ≤ 93% 12-24 h postoperatively (Table 2 ).
Discussion
Major postoperative pulmonary complications rarely occurred in both the conventional and the HHFNC O 2 groups included in this pilot study. There were no statistically significant differences for the primary outcome of postoperative pulmonary complications in patients treated with HHFNC versus conventional O 2 . Of the secondary outcomes, only the number of hourly measurements of SpO 2 ≤ 93% 12-24 h postoperatively showed a statistically significant, yet clinically insignificant difference (0.7 vs. 1.4 episodes in the HHFNC vs. conventional O 2 groups). Prophylactic administration of HHFNC O 2 was not well tolerated; 7/25 (28%) of patients elected to discontinue therapy prior to 48 h or prior to transfer from the ICU to the floor. An additional 4/25 (16%) complained of discomfort with the HHFNC O 2 , yet elected to continue treatment.
Although in this pilot study routine prophylactic HHFNC did not convey any benefit to a cohort of postoperative thoracic surgery patients, our results have to be interpreted with caution, as our study was underpowered to detect a difference in the primary composite outcome of postoperative pulmonary complications. This is likely because, in the planning stages of our study, several conditions were different than during the period when the study was implemented. For example, the approach to one of the most morbid thoracic procedures -esophagectomy -was changed from being performed commonly in an open to a minimally-invasive/thoracoscopic approach [20] . More severe pain from a thoracotomy incision has been associated with higher incidences of pulmonary complications after thoracic surgery [1] . Furthermore, implementation of enhanced recovery pathways, more advanced perioperative monitoring technologies [21, 22] , changes in surgical staff, as well as non-standardized algorithms for the detection of postoperative pulmonary complications in the historical cohort, could have led to a lower incidence of postoperative pulmonary complications in our study. Indeed, our overall rate of 7% for postoperative pulmonary complications was more consistent with recently reported rates of 8.5% for respiratory failure requiring re-intubation in non-cardiac surgery in surgical ICUs [23] . [18] . Table 1 Demographics of study population. Simplified Acute Physiology Score (SAPS II). P-value refers to the comparison between the HHFNC O 2 and the control group. ASA Status refers to the physical status classification system by the American Society of Anesthesiologists (no emergent cases were present in the study cohort). VATS = video-assisted thoracoscopic surgery. PRBCs = packed red blood cells. 19 [7] 23 [7] 0.082 [24] . Similarly, it may be worthwhile to develop algorithms for the ideal time to discontinue HHFNC O 2 as to best realize its benefits and minimize patient discomfort from the HHFNC O 2 therapy.
Conclusions
In conclusion, in this prospective randomized pilot trial comparing HHFNC O 2 to conventional O 2 therapy, major postoperative pulmonary complications were rare, and a beneficial effect of HHFNC O 2 could not be ascertained. Relatively high rates of patient-reported discomfort should be taken into account when deciding on initiation and termination time points of this therapy to low-risk patients.
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